Jackie Walling

Jackie Walling, MBChB, PhD, is a British trained physician scientist and the principal of a consulting group that provides expertise on a wide range of global drug development and regulatory projects in oncology and rare diseases. Her leadership has directly impacted the successful development and regulatory approval of several medicines including gemcitabine, pemetrexed, elosulfase, relugolix and talazoparib. Dr. Walling received an MBChB from the University of Bristol and BSc and PhD degrees from the University of Southampton, UK.